Navigation Links
Vical Licensee AnGes MG Files NDA in Japan for Collategene Angiogenesis Product
Date:3/28/2008

SAN DIEGO, March 28 /PRNewswire-FirstCall/ -- Vical Incorporated (Nasdaq: VICL) today announced the company's licensee, AnGes MG, Inc., reported submission on March 27, 2008, of a New Drug Application (NDA) to the Japanese Ministry of Health, Labor and Welfare for its angiogenesis product candidate, Collategene, for treatment of critical limb ischemia. The treatment uses Vical technology to deliver a gene encoding hepatocyte growth factor (HGF), a human protein that causes growth of blood vessels in areas of restricted blood flow.

"The Japanese NDA filing positions Collategene to be the first product based on our DNA delivery technology with the potential to be approved for human use," said Vijay B. Samant, President and Chief Executive Officer of Vical. "In the United States, where it is estimated that more than 10 million people have peripheral arterial disease (PAD), AnGes already has completed two Phase 2 clinical trials of Collategene in PAD patients. This product candidate offers a novel approach to addressing an important, unserved medical need in the Japanese market, and has the potential to expand into the much larger markets worldwide. This NDA filing by AnGes is an important milestone in advancing nonviral gene therapy toward regulatory and commercial acceptance."

The NDA submission follows positive results announced in June 2007 following interim analysis of data from the first 41 subjects to complete a Phase 3 trial of Collategene. Based on the findings that the primary efficacy endpoint in the trial had been achieved with statistical significance and that there were no major safety concerns related to treatment, an Independent Data Monitoring Committee recommended stopping the trial early to prevent potential e
'/>"/>

SOURCE Vical Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Vical to Present at Cowen and Company Health Care Conference
2. Vical to Present at BIO and BVGH Global Health Partnering Event
3. Survey Shows Most Women Cant Separate Fact From Fiction When It Comes to Cervical Cancer Prevention
4. Vical to Participate in Pandemic Influenza Panel at JPMorgan Healthcare Conference
5. New Online Learning Tool Fills the Knowledge Gap on Botulinum Toxin Type B for Cervical Dystonia
6. Vical Launches Redesigned Website
7. Vical Presentation at Military Pandemic Influenza Workshop
8. Amedica Receives FDA 510(k) Clearance for Valeo(TM) Cervical Plate
9. Vical to Present at Investor Conferences
10. Diamics Receives European CE Mark Approval for Its Pap-Map(TM) System for Cervical Cancer Screening
11. Vical Announces News Release and Conference Call Schedule for Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... 30, 2015 Richmond Pharmacology ... Richmond Pharmacology ist das erste Zentrum weltweit, das ... Free Hospital in London ... RNAi-Therapeutikums Studienversuche an einem Patienten begonnen hat. Das ... Amyloidose entwickelt (ATTR), einer seltenen Herz- und Nervenkrankheit. ...
(Date:3/29/2015)... As a symbol of its commitment to ... manufacturing clients, Whitehouse Laboratories is excited to announce that ... Team for the 2015 race season. Success on the ... strong sense of precision and attention to detail. These ... the quality control testing laboratory. Sponsorship of the race ...
(Date:3/27/2015)... 27, 2015   SurePure, Inc . (OTCQB: ... today that the Company has completed the verification ... of SurePure ("SURP") securities on OTCQB, an electronic ... and development stage companies. On March ... eligibility requirements designed to improve marketplace integrity and ...
(Date:3/27/2015)... 2015 Governor Andrew M. Cuomo today ... 43North - the world’s largest business idea competition with ... of $1 million, six $500,000 awards and four $250,000 ... to compete for prizes that will turn ideas with ... New York region. , "Last year's successful 43North ...
Breaking Biology Technology:Whitehouse Laboratories Reaffirms Commitment to Speedy Results – Renews Sponsorship of Berkenstock Racing Team 2SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 2Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 3Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 4Governor Andrew M. Cuomo Anounces Launch of Year Two of World's Largest Business Idea Competition and Opening of New Incubator Space in Buffalo, New York 5
... June 16 Naviscan PET Systems(R), a company,specializing ... the Society of Nuclear Medicine,s Annual Meeting, new ... cancer management. The PEM,Flex(TM) Solo II is a ... for the breast application known as positron,emission mammography, ...
... Medullary Thyroid Cancer Planned to Initiate This Summer, ... Inc. (Nasdaq: EXEL ) announced today that ... (FDA) have reached agreement on the phase 3,registration ... targeting,MET, RET, and VEGFR2, via the Special Protocol ...
... NDC #58177-320-04 & 58177-330-04 ... Lot Numbers listed below, ST. ... recalled specific additional lots of morphine,sulfate 60 mg extended release tablets, ... a precaution, due to the,possible presence of oversized tablets. Oversized tablets ...
Cached Biology Technology:Naviscan's PEM Flex(TM) Detects Smallest Cancers Better Compared to MRI in an Independent Study 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 2Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 3Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 4Exelixis Reaches Agreement with FDA on Special Protocol Assessment for XL184 Phase 3 Trial 5ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 2ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 3ETHEX Corporation Voluntarily Recalls Specific Lots of 30 mg. and 60 mg. Morphine Sulfate Extended Release Tablets Due to the Potential for Oversized Tablets 4
(Date:3/19/2015)... Inc. (NASDAQ: NXTD ) ("NXT-ID" or the "Company"), ... market, announces its biometric payment technology, the Wocket® smart wallet ... on Washington DC,s Fox 5 News ... Next Great Thing", host Laura Evans calls the ... really big breakthrough in mobile payment.,  Award-winning ...
(Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
(Date:3/17/2015)... , March 17, 2015  MecklerMedia Corporation (OTCQX: ... exhibition for service robots ever held in ... place on May 11-13, 2015 at the Javits ... for the event include: Acorn Product Development; Axis ... Infranor; Kinova Robotics; Littler; NewBotic Corporation; Neya Systems ...
Breaking Biology News(10 mins):NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 2NXT-ID's Wocket Smart Wallet Featured on Fox News Segment, "The Next Great Thing" 3Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2
... Brine water that flows back from gas wells in ... times more salty than seawater, with high contents of ... consistent with brines formed during the Paleozoic era, a ... Penn State,s Department of Geosciences found. The study indicates ...
... of Energy,s National Renewable Energy Laboratory (NREL) will partner ... a five-year, $7 million effort to economically produce drop-in ... the federal laboratory announced today. The work will ... (CRADA) between NREL and Johnson Matthey. "It,s a ...
... The Hass Avocado Board (HAB) is supporting ... benefits of consuming fresh avocados to human health ... investigate the relationship between avocado consumption and risk ... in weight management and diabetes, and avocados, ability ...
Cached Biology News:Analysis of Marcellus flowback finds high levels of ancient brines 2NREL and Johnson Matthey announce 5-year collaboration on biofuels 2Hass Avocado Board study published in Food & Function journal 2
Autoclavable, variable volumefitted w./ an anti-drip safety valve; borosilicate glass barrelprotected with transparentpolypropylene sleeve; spring-lock cursor design ensuresfine adjustment for exact ...
Spaced cover glasses to promote effective hybridization...
Disposable tips with floating filter (US Patent 6,702,990) for PDM1.5 OneTouch Plus spotpicker, 10 racks of 96, DNAse and RNAse free...
... new D-LUX Detection Platform combines robust ... the most sensitive, specific, and cost-effective ... D-LUX Detection Platform offers exceptional performance ... TaqMan probes, high signal/background ratio, and ...
Biology Products: